Bausch + Lomb Corp (BLCO) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Bausch + Lomb Corp $9.93, price $17.05, upside -41.8%, quality 38 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Bausch + Lomb Corp for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
53‑month range $10.90 – $20.99 · fair‑value band $3.95 – $15.90 · the $17.05 price screens above the $9.93 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Bausch + Lomb in your weekly email
Every Wednesday you see whether Bausch + Lomb is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical.
Show more
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provide optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.
Stock analysis
Bausch + Lomb Corp (BLCO) currently trades at $17.05, while our model-based Fair Value estimate is $9.93, implying the stock looks roughly 71.7% overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 5 models at a data quality of 94/100, which puts the evidence level at medium.
Scenario range: $3.95 (bear) to $15.90 (bull), the price of $17.05 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 38/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Bausch + Lomb Corp reported revenue of $5.1B in FY2025 versus $3.8B in FY2021, a compound +7.9%/yr. Reported net income was −$360M in FY2025.
Key figures
Market cap $6.0B · P/S ratio 1.11 · EPS (TTM) $−0.6200 · Net margin −7.1% · Return on equity −3.3% · Return on assets (EBIT) 1.7% · Operating margin 4.7% · Revenue (TTM) $5.2B.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 47 out of 100 (low confidence).
What moves the price
The share trades about 8% below its 52-week high and 19% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −12% fair-value upside, at −42%, BLCO screens richer than that median.
Fair Value models
Bear $3.95Fair Value $9.93Bull $15.90
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.31/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+6.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.4%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.8%
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
7.6% (2020) → 3.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
News mood ⓘNews mood, the average tone of recent news (97 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Positive
Recent news coverage is more positive than average.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 205 stocks
Beats the industry median on 3/10 measures
Overall it trails its industry peers.
Valuation
Quality Score38 · Bottom 25%
Fair Value upside−42% · Below median
Profitability
Return on assets1% · Below median
Net margin (TTM)−4% · Bottom 25%
Operating margin (TTM)5% · Below median
Growth and dividend
Revenue growth9% · Above median
Balance sheet
Debt / equity0.78× · Highest 25%
Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper
P/B0.94× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (TTM)1.16× · Cheaper than median
EV/EBITDA14.8× · Pricier than median
PEG0.89× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 20
FUTURE (revenue growth)47· sector 28
PAST (return on equity)0· sector 25
HEALTH (low debt)61· sector 96
DIVIDEND (yield)0· sector 32
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Bausch + Lomb Corp (BLCO) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $9.93 versus a price of $17.05, about −42% upside (overvalued).
What is the fair value of BLCO?
Our model-based fair value for Bausch + Lomb Corp is $9.93 (as of Sep 24, 2026), built from audited fundamentals. The current price: $17.05.
What is the quality score of BLCO?
Bausch + Lomb Corp has a Quality Score of 38/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Bausch + Lomb Corp (BLCO)?
Our model-based price target is the fair value of $9.93 (as of Sep 24, 2026) from 2 valuation models. Cautious scenario $3.95, optimistic scenario $15.90. It is a calculation from audited fundamentals, not an analyst target.
What is the Bausch + Lomb Corp stock forecast for 2026?
Our models put fair value at $9.93, about −42% upside versus a price of $17.05 (overvalued). Cautious scenario $3.95, optimistic scenario $15.90. The calculation is refreshed regularly with new filings.
What is the revenue of Bausch + Lomb Corp (BLCO)?
Bausch + Lomb Corp reported trailing-twelve-month revenue of about $5.2B (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Bausch + Lomb Corp (BLCO)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Bausch + Lomb Corp it is $9.93 per share (as of Sep 24, 2026), against a price of $17.05. It is the blended result of 2 valuation models (cash flow, earnings, asset, dividend).
Is Bausch + Lomb Corp stock overvalued or undervalued in 2026?
As of Sep 24, 2026, BLCO trades above its calculated fair value: price $17.05, fair value $9.93, a gap of about −42% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BLCO?
No. The price is what the market pays today ($17.05); the fair value is what the company's own numbers justify ($9.93). For Bausch + Lomb Corp the two are $7.12 per share apart. That gap is exactly why we show both numbers side by side.
How much is Bausch + Lomb Corp worth?
The market values Bausch + Lomb Corp at about $6.0B (market capitalisation, as of Sep 24, 2026). Per share that is $17.05; our models calculate a fair value of $9.93 per share.
What do the bullish and bearish scenarios say about BLCO?
Our models span a range for Bausch + Lomb Corp: cautious scenario $3.95, base $9.93, optimistic $15.90 per share (as of Sep 24, 2026, price $17.05). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of BLCO?
The PEG ratio of Bausch + Lomb Corp is 0.89 (P/E divided by earnings growth, as of Sep 24, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Bausch + Lomb Corp (BLCO)?
Balance-sheet figures for Bausch + Lomb Corp (as of Sep 24, 2026): return on equity −3.3%, debt of 0.78 per unit of equity. They feed the Quality Score of 38/100, which measures business quality independently of the share price.
How far is BLCO from its 52-week high?
Bausch + Lomb Corp trades at $17.05, about 8% below its 52-week high of $18.60 and 19% above the low of $14.32 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $9.93 is for.
Which stocks are comparable to Bausch + Lomb Corp?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Medline Inc, Becton, Dickinson and Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Bausch + Lomb Corp stock attractive at the current price?
The data as of Sep 24, 2026: price $17.05, calculated fair value $9.93 (−42%), Quality Score 38/100, from 2 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BLCO calculated?
We run Bausch + Lomb Corp through 2 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $9.93, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Bausch + Lomb Corp itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Bausch + Lomb Corp (BLCO)?
The closing price on Sep 23, 2026 was $17.05. Our model-based fair value is $9.93, about −42% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Bausch + Lomb Corp right now?
The price sits above even our optimistic bull case ($15.90). The favourable scenario is already priced in. Weak quality (38/100) and above fair value at the same time, the margin of safety is missing on both counts. The model range is unusually wide ($3.95 to $15.90). The outcome hinges heavily on assumptions, so read the point estimate with caution.
Key figures of Bausch + Lomb Corp
How large is the market capitalisation of Bausch + Lomb Corp (BLCO)?
The market capitalisation of Bausch + Lomb Corp is $6.0B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Bausch + Lomb Corp (BLCO)?
The price-to-sales ratio of Bausch + Lomb Corp is 1.11 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Bausch + Lomb Corp (BLCO)?
Earnings per share at Bausch + Lomb Corp are $−0.6200. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Bausch + Lomb Corp (BLCO)?
The net margin of Bausch + Lomb Corp is −7.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Bausch + Lomb Corp (BLCO)?
The return on equity (ROE) of Bausch + Lomb Corp is −3.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Bausch + Lomb Corp (BLCO)?
On an EBIT basis the return on assets of Bausch + Lomb Corp is 1.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Bausch + Lomb Corp (BLCO)?
The operating margin of Bausch + Lomb Corp is 4.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Bausch + Lomb Corp (BLCO)?
Revenue at Bausch + Lomb Corp is growing +9.4% versus a year earlier (3y avg +10.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Bausch + Lomb Corp (BLCO)?
Earnings per share at Bausch + Lomb Corp are growing −88.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Bausch + Lomb Corp (BLCO) generate?
The free cash flow of Bausch + Lomb Corp is −$66.0M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Bausch + Lomb Corp (BLCO) carry?
The net debt of Bausch + Lomb Corp is $5.0B (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Bausch + Lomb Corp in the live analysis
One click puts Bausch + Lomb Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Some data
Sep 24, 2026